Cereda, Cw; Zecca, C; Mazzucchelli, L; Valci, L; Staedler, C; Bassetti, Cl; Gobbi, C (2013). Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy. Multiple sclerosis journal, 19(6), pp. 820-3. London: Sage 10.1177/1352458512461969
Full text not available from this repository. (Request a copy)Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-α antagonist (anti-TNF-α) acting as a soluble TNF-α receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -α antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy confirmed the inflammatory demyelinating nature of the lesions. The clinical presentation is unusual due to the severity of the disease process, requiring decompressive hemicraniotomy with a clinically favorable outcome.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Bassetti, Claudio L.A. |
ISSN: |
1352-4585 |
Publisher: |
Sage |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:39 |
Last Modified: |
02 Mar 2023 23:21 |
Publisher DOI: |
10.1177/1352458512461969 |
PubMed ID: |
23069873 |
Web of Science ID: |
000318637900018 |
URI: |
https://boris.unibe.ch/id/eprint/15882 (FactScience: 223376) |
Actions (login required)
 |
Edit item |